Evidence map›Paper›PMID 39721693›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab.

Takuma Tsuzuki Wada, Kazuhiro Yokota, Mariko Okada, Takaya Ichimura, Takehito Ueno, Nobuhito Okumura, Iichiro Osawa, Kaiji Inoue, Yuji Akiyama, Yoshihiko Nakazato and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takuma Tsuzuki WadaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Kazuhiro YokotaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Mariko OkadaDepartment of Neurology, Faculty of Medicine, Saitama Medical University, Japan.
Takaya IchimuraDepartment of Pathology, Faculty of Medicine, Saitama Medical University, Japan.
Takehito UenoDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Nobuhito OkumuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Iichiro OsawaDepartment of Radiology, Saitama Medical University Hospital, Japan.
Kaiji InoueDepartment of Radiology, Saitama Medical University Hospital, Japan.
Yuji AkiyamaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Yoshihiko NakazatoDepartment of Neurology, Faculty of Medicine, Saitama Medical University, Japan.
Atsushi SasakiDepartment of Pathology, Faculty of Medicine, Saitama Medical University, Japan.
Toshimasa YamamotoDepartment of Neurology, Faculty of Medicine, Saitama Medical University, Japan.
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.

Indexed as

Antibodies, Monoclonal, HumanizedCastleman DiseaseNeuromyelitis OpticaFemaleHumansMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedtocilizumabCastleman diseaseinterleukin-6neuromyelitis optica spectrum disordertocilizumab

Identifiers

PMID39721693
PMCPMC12287589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.